Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

The Quick Take
Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.
Ground Level News gathers headlines from public news feeds. This page shows a short summary only; the full article and all rights belong to CNBC.



